Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 145 participants.

Also called NCT06955104

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 145 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06955104
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06955104. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-03 (actual); primary completion 2025-07-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia
Condition
Dyslipidemia
Intervention (Drug)
JW0108 + C2407
Intervention (Drug)
JW0108 + C2407 placebo
Lead sponsor
JW Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct06955104
Content hash
2b129dbaffbd89a3e10a4ea68e0d1ac7891b603bb4e2b5cc6525c2998a0a1903